Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 14 May 2026 for Apellis Pharmaceuticals, Inc.. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Gerald Chan: trading record in brief
Gerald Chan, listed as senior executive, appears in our data through filings on Apellis Pharmaceuticals, Inc. shares, published by SEC (Form 4). We count 6 filings; the first trade dates from 1 January 2022 and the latest from 14 May 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
On 14 May 2026 came the latest disclosure, a transaction in Apellis Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Gerald Chan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
25,666 sharesCommon StockSEC:0001193125-26-224606:0
7,961 shares0Common StockSEC:0001492422-26-000012:0
6,267 shares0Common StockSEC:0001127602-25-000400:0
3,341 shares0Common StockSEC:0001127602-24-000114:0
3,867 shares0Common StockSEC:0000899243-23-000670:0
4,230 shares0Common StockSEC:0001127602-22-000727:0
6 of 6 declarations
